CoDa Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
CoDa Therapeutics has novel wound care technology that suppresses connexins, the proteins that make up gap junctions. In preclinical studies the company's drugs reduced gap junction formation and communication, as well as inflammation, swelling and scarring, and doubled wound healing rates.